Increasing MDSCs during the early stages of COVID-19 were correlated with IL-1β, IL-6, IL-8, and TNF-α plasma levels, particularly in patients who required intensive care treatments, suggesting new therapeutic options geared toward MDSCs42. Here, CXCL8 is linked to COVID-19.